You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Pulmonology

ERS 2023 | Advancing Asthma Management Beyond Control

Prof. Ian Pavord discusses the current proposed framework for clinical remission in severe asthma.

Ian D. Pavord
DM, FERS, FMedSci, FRCP
Ian D. Pavord

Learning objectives

  • Discuss the components of the evolving definition of on-treatment clinical remission in asthma
  • Evaluate the latest data supporting achievement of on-treatment clinical remission with biologics in severe asthma patients
  • Understand how type 2 inflammatory biomarkers can be useful in identifying patients and managing their asthma with on-treatment clinical remission as the goal

Description

In this video highlight from the ADVENT adult asthma symposium at ERS 2023, Ian Pavord, DM, FRCP, FERS, FMedSci, presents the latest criteria for defining the clinical remission status of asthma patients as outlined in professional guidelines and publications.

Tags
guidelinesremission
MAT-GLB-2304095 v2.0 10/2023

About this expert

Pulmonology

Ian D. Pavord

DM, FERS, FMedSci, FRCP

Professor of Respiratory Medicine | University of Oxford; Honorary Consultant Physician | Oxford University Hospitals, United Kingdom

See author’s profile
Ian D. Pavord

Related resources

ERS 2023 | Adult Asthma Symposium: Mini Debate
Pulmonology
expert video

ERS 2023 | Adult Asthma Symposium: Mini Debate

ERS 2023 | Adult Asthma Symposium: Panel Discussion
Pulmonology
expert video

ERS 2023 | Adult Asthma Symposium: Panel Discussion

ERS 2023 | Advancing Asthma Management Beyond Control
Pulmonology
expert video

ERS 2023 | Advancing Asthma Management Beyond Control

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma
Pulmonology
expert video

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma
Pulmonology
expert video

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Evolving Patient Care: From Symptom Control to On-Treatment ​Clinical Remission​
Pulmonology
expert video

ERS 2023 | Evolving Patient Care: From Symptom Control to On-Treatment ​Clinical Remission​

ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?
Pulmonology
expert video

ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?

ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?
Pulmonology
expert video

ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion
Pulmonology
expert video

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma
Pulmonology
expert video

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management
Pulmonology
expert video

ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management

How Can Biologics Improve Lung Function in Pediatric Severe Asthma?
Pulmonology
expert video

How Can Biologics Improve Lung Function in Pediatric Severe Asthma?

GINA Asthma Decision Tree
Pulmonology
videoanimation

GINA Asthma Decision Tree

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters
Pulmonology
expert video

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters

Effects of OCS Use Over a Patient’s Lifetime
Pulmonology
expert video

Effects of OCS Use Over a Patient’s Lifetime

Asthma White Board Video
Pulmonology
videoanimation

Asthma White Board Video

Type 2 Inflammation Underpins Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?
Pulmonology
expert video

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age
Pulmonology
interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?
Pulmonology
expert video

ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?

GOLD 2024 Diagnosis and Assessment of COPD
Pulmonology
expert video

GOLD 2024 Diagnosis and Assessment of COPD

Importance of Lung Function Assessment in Pediatric Asthma Patients
Pulmonology
videoanimation

Importance of Lung Function Assessment in Pediatric Asthma Patients

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?
Pulmonology
Podcast

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care
Pulmonology
videoanimation

Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care

How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?
Pulmonology
videoanimation

How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Pulmonology
expert video

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission
Pulmonology
expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma
Pulmonology
expert video

EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care
Pulmonology
expert video

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond
Pulmonology
Podcast

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE
Type 2 Inflammation
Infographic

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma
Pulmonology
Podcast

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Eosinophils as a Biomarker for Type 2 Asthma
Pulmonology
expert video

Eosinophils as a Biomarker for Type 2 Asthma

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
Pulmonology
expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden
Pulmonology
expert video

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

ERS 2024 | Understanding the Complex Pathophysiology of COPD
Pulmonology
expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

COPD and Asthma: What's the Difference and Is There a Link?
Pulmonology
interactivity

COPD and Asthma: What's the Difference and Is There a Link?

ERS 2023 | Heterogeneity of Inflammatory Pathways in COPD
Pulmonology
expert video

ERS 2023 | Heterogeneity of Inflammatory Pathways in COPD

Type 2 Inflammation Digital Assessment Tool
Pulmonology
interactivity

Type 2 Inflammation Digital Assessment Tool

Adult Asthma Interactive Patient Cases
Pulmonology
interactivity

Adult Asthma Interactive Patient Cases

What Do We Know About Type 2 Inflammation in COPD?
Pulmonology
expert video

What Do We Know About Type 2 Inflammation in COPD?

On-Treatment Asthma Remission: Moving Beyond Control
Pulmonology
interactivity

On-Treatment Asthma Remission: Moving Beyond Control

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity
Pulmonology
interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

ERS 2023 | Contextualizing Clinical Presentation of COPD Through Disease Pathology
Pulmonology
expert video

ERS 2023 | Contextualizing Clinical Presentation of COPD Through Disease Pathology

The Heterogeneity of Underlying Inflammation in Patients With COPD
Pulmonology
expert video

The Heterogeneity of Underlying Inflammation in Patients With COPD

ERS 2023 | The Impact of Type 2 Inflammation on COPD: Examining Its Role in Disease Pathophysiology
Pulmonology
expert video

ERS 2023 | The Impact of Type 2 Inflammation on COPD: Examining Its Role in Disease Pathophysiology

GOLD 2023 | Beyond a One Size Fits All Approach: Recognizing the Heterogeneity of COPD
Pulmonology
expert video

GOLD 2023 | Beyond a One Size Fits All Approach: Recognizing the Heterogeneity of COPD

GOLD 2023 | Role of Underlying Inflammation in COPD Pathology and Clinical Features
Pulmonology
expert video

GOLD 2023 | Role of Underlying Inflammation in COPD Pathology and Clinical Features

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video
Pulmonology
videoanimation

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

Pathways to Disease: Inflammation in COPD
Pulmonology
interactivity

Pathways to Disease: Inflammation in COPD

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region